Jessica Vega Says a GLP-1 Helped Her Stop Drinking — What Does the Research Actually Show?

Medical note: This article discusses alcohol use disorder and an experimental treatment question. GLP-1 medications are not currently FDA-approved to treat alcohol use disorder.

Jessica Vega says she has not had a drink since receiving her first GLP-1 injection in January. Her story, published by People on September 17, is striking because she describes something many people in recovery know very well — the exhausting pull of craving — becoming dramatically quieter.

That makes for a powerful headline. It also makes this exactly the kind of story that needs careful handling.

Vega’s experience is one person’s experience. It is not proof that GLP-1 drugs “cure” alcohol addiction. At the same time, the idea is no longer just internet anecdote: early randomized research has found signals that semaglutide may reduce some measures of alcohol craving and consumption. The science is interesting. It is also preliminary.

The deeper recovery question is worth asking now: if medicine can someday make craving quieter, what does that change about the way we talk about willpower, shame and addiction?

What happened to Jessica Vega?

Vega, 44, told People that she had been drinking daily and was living in a Rhode Island shelter when she finally told a social worker she needed help. Through OpenDoors’ She Thrives program, she was referred to a physician who determined that a GLP-1 medication was medically appropriate for her.

Vega says she was skeptical. She had tried Alcoholics Anonymous years earlier and did not believe an injection associated in the public mind with diabetes and weight loss could change a serious alcohol problem.

Then, she says, something changed quickly: alcohol became unappealing. She describes being around alcohol during a family trip months later without the craving she once expected. She says she has remained alcohol-free since the first injection and has also been rebuilding her relationship with her children.

OpenDoors itself is careful about the claim. Its co-executive director told People that 23 people had participated in the program and that the organization’s experience is anecdotal, not a scientific study. Some participants reported reduced cravings; others relapsed, did poorly or were lost to follow-up.

That is an important detail because one dramatic success story can make an emerging treatment look much more settled than it actually is.

What does the research on semaglutide and alcohol actually show?

A 2025 randomized clinical trial published in JAMA Psychiatry tested once-weekly semaglutide in 48 adults with alcohol use disorder. It was a small phase 2 study, so it should be read as an early signal rather than a final answer.

Compared with placebo, semaglutide significantly reduced the number of drinks consumed on drinking days and reduced weekly alcohol craving. It was also associated with greater reductions in heavy-drinking days over time.

But the study did not show a significant effect on average drinks per calendar day or on the number of drinking days. The researchers themselves described several outcomes as exploratory or hypothesis-generating and called for larger trials.

That mixed picture is more useful than either extreme headline.

“GLP-1 drugs have nothing to do with alcohol” is too dismissive for the evidence we now have.

“Ozempic cures alcoholism” is far beyond the evidence we have.

Right now, the accurate middle is: there is enough evidence to justify serious research, but not enough to treat GLP-1 medication as an established AUD therapy.

The National Institute on Alcohol Abuse and Alcoholism currently lists three FDA-approved medications for alcohol use disorder in the United States: naltrexone, acamprosate and disulfiram. Semaglutide and other GLP-1 drugs are not on that approved list for AUD.

Why the Reddit conversation matters — and where it does not

GLP-1 and alcohol threads have been active across Reddit throughout 2026. Some people describe unexpectedly losing interest in alcohol after starting a GLP-1 medication. Others ask whether they should seek the drug specifically for cravings. Still others are worried about side effects, access, cost or whether an anecdotal improvement will last.

That discussion tells us something important about demand: people are already asking the question before medicine has a definitive answer.

It does not tell us whether the treatment works. Reddit is useful here as a window into what people are wondering, not as clinical evidence.

And I think one recurring reaction is especially revealing: people are surprised that a craving could become quieter without a heroic battle of willpower.

If craving gets quieter, was your recovery “less earned”?

This is where the story becomes bigger than one drug.

Recovery culture can sometimes carry a strange moral hierarchy. We admire the person who white-knuckles through unbearable craving. We talk about discipline, surrender, commitment and strength. Those things can matter.

But if a medication safely reduces craving, that does not make the person less serious about recovery.

We already accept that some people use naltrexone or acamprosate as part of alcohol treatment. Some use therapy. Some use mutual-help groups. Some use structured outpatient programs. Some use several of these at once.

Suffering is not the admission price for recovery.

A tool does not erase the choices that follow it. Even in Vega’s own telling, medication did not rebuild every part of her life for her. She still had to tell the truth, accept help, remain engaged with care and repair relationships.

That is why I would not frame this as “medicine versus willpower.” That is the wrong contest.

The better question is whether a treatment can make recovery more possible for a particular person, with appropriate medical care and enough evidence to justify its risks.

What this story does not mean

It does not mean someone with alcohol dependence should obtain a GLP-1 drug on their own or stop drinking abruptly because they read a success story. Alcohol withdrawal can include seizures and other serious complications; people who may be physically dependent should talk with a qualified clinician about how to stop safely.

It does not mean GLP-1 medications are harmless. They have contraindications and potential adverse effects, and their risks and benefits belong in a medical conversation.

And it does not mean existing AUD treatments are obsolete. NIAAA describes both behavioral care and approved medications as evidence-based options, often used together.

For a deeper look at the identity side of choosing an alcohol-free life, see Alcohol-Free Without a Recovery Label: Building an Identity That Fits. If you are supporting someone else rather than making the decision for yourself, How Families Can Support Recovery Without Controlling It looks at the difference between helping and taking over.

The OliviaC reflection

There is a reason stories like Jessica Vega’s feel almost unbelievable.

We are used to talking about addiction as a fight between a person and a substance, with character standing in the middle as the referee.

But addiction has never been only a character problem.

Biology matters. Environment matters. Pain matters. Learning matters. Access to care matters. Relationships matter. And personal agency still matters inside all of that.

If future trials show that GLP-1 medications meaningfully help some people with alcohol use disorder, I hope the lesson is not that we found an “easy way out.”

I hope the lesson is that we found another tool.

Recovery does not become more meaningful because craving was louder. It becomes meaningful because a person gets more life back.

Continue the Story

Go Deeper

Sources

• People, September 17, 2026 — Jessica Vega’s account and comments from addiction specialists and OpenDoors.
• JAMA Psychiatry, 2025 — randomized phase 2 trial of once-weekly semaglutide in 48 adults with alcohol use disorder.
• NIAAA — evidence-based AUD treatment and currently FDA-approved AUD medications.
• Recent Reddit discussions were reviewed only as evidence of public interest and recurring questions, not as medical evidence.

Featured image: chemical structure of semaglutide by Edgar181 / Wikimedia Commons; public domain. Semaglutide is the drug studied in the cited randomized trial. The image does not identify the specific GLP-1 medication prescribed to Jessica Vega.

Medical safety note: This article is informational and does not recommend starting, stopping or changing any medication. GLP-1 medications are not currently FDA-approved for alcohol use disorder. If you may be physically dependent on alcohol, seek medical guidance before stopping suddenly because withdrawal can become medically serious.